TCR-based Therapies for Solid Tumors Summit
Evvnt Promotion / evvnt
Archivio
03.04.2023 - 05.04.2023 Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, Massachusetts, USA
Time: 09:00 to 16:30
Temi della conferenza
The first TCR-based therapy approval in the US and Europe at the start of this year sparked a rush of excitement, investment and collaborations. As further developers move into the clinic and some near commercialization, it's time for this community to unite to address the critical bottlenecks faced in development, from discovery to approval, to guarantee smooth sailing through the clinic.
The first TCR-based therapy approval in the US and Europe at the start of this year sparked a rush of excitement, investment and collaborations. As further developers move into the clinic and some near commercialization, it's time for this community to unite to address the critical bottlenecks faced in development, from discovery to approval, to guarantee smooth sailing through the clinic.
Scientific organizer
Hanson Wade
Hanson Wade
Annotazioni
Brochure: https://go.evvnt.com/1444012-3?pid=4832
Speakers: Birgit Schultes, Senior Vice President, Cell Therapy, Intellia Therapeutics, Claudia Wagner, Senior Director, Immunology, Head of TCR Discovery and Validation, Immatics, and more
Brochure: https://go.evvnt.com/1444012-3?pid=4832
Speakers: Birgit Schultes, Senior Vice President, Cell Therapy, Intellia Therapeutics, Claudia Wagner, Senior Director, Immunology, Head of TCR Discovery and Validation, Immatics, and more
Informazioni ed Iscrizioni:
https://go.evvnt.com/1444012-2?pid=4832
Ms. Ellie Saunders
Medicina General
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
